PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Contraception, Postcoital”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1990

Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two danazol regimens.

The ethinylestradiol-norgestrel combination (EE-NG) for postcoital contraception, as described by Yuzpe, has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects a new approach using danazol was proposed, but the efficacy and acceptability of this treatment have not yet been tested in large studies. In a 5-year period at the AIECS Family Planning Centre in Milan we treated 2448 women requesting postcoital contraception using Yuzpe's regimen and two danazol regimens (800 mg/1200 mg). The patients' acceptability for danazol treatment was higher than for Yuzpe's regimen due to fewer, milder and shorter side effects. Nine pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%) and 6 in the 1200 mg group (0.82%). Our study shows a statistically significant efficacy against expected pregnancy rates both with Yuzpe's regimen and with danazol. The 1200 mg danazol treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception.

Adolescent↗
PubMedDate not supplied

Alternative treatments in oral postcoital contraception: interim results.

The study compares the effectiveness and acceptability of three regimes of postcoital contraception: 1) ethinylestradiol 100 micrograms/levonorgestrel 500 micrograms repeated after 12 hours (Yuzpe method); 2) danazol 600 mg repeated after 12 hours; and 3) RU486 600 mg single dose. Between 1 April 1990 and 15 October 1990, 215 women were selected and randomly allocated to the three treatment groups. One hundred and sixty eight were fully followed up, 35 ongoing and 8 lost to follow-up. All women had regular cycles and were aged 16-45 years. All treatments were given within 72 hours of unprotected intercourse and follow-up was until normal menstruation or diagnosis of pregnancy. beta-HCG was measured quantitatively where there was a suspicion of pregnancy. The data obtained show similar failure rates (Yuzpe 1/57, danazol 2/57, RU486 1/54) but more side-effects in the Yuzpe group (nausea 74.1%, vomiting 22.4%, breast tenderness 22.4%) than in the other two (danazol: nausea 31.6%, vomiting 3.5%, breast tenderness 19.3%) and (RU486: nausea 36.4%, vomiting 3.6%, breast tenderness 23.6%). There was one apparent allergic reaction in the danazol group. RU486 caused greater cycle disturbance, prolonging the cycle considerably. Initial results suggest that danazol and RU486 may be much more acceptable methods of postcoital contraception due to reduced side-effects and, in the latter case, single dose. Although numbers are small at present, the effectiveness of the newer methods appear similar to Yuzpe.

Abortifacient Agents↗
PubMed1983

Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.

A combination of 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol (EE) was administered orally at 36 hours after the detection of the luteinizing hormone peak and again at 48 hours in 12 healthy volunteers with normal menstrual cycles. The effects on ovarian function were studied by comparing the daily serum levels of progesterone (P), 17 alpha-hydroxyprogesterone, and estradiol (E2) in control (placebo) and treatment cycles. Five subjects showed no significant change in the levels of these steroids but had a shortened luteal phase. The treatment significantly decreased both P and E2 levels in three subjects, while two subjects showed diminished E2 levels only. The remaining two subjects had lower P levels and fluctuating E2 patterns. Endometrial biopsies from both study cycles indicated asynchronous development of the epithelial and stromal components in the treatment cycle. These findings (abnormal luteal phase steroid levels and duration and outphased endometrial development) indicate that corpus luteum function was variously affected by the action of norgestrel-EE treatment.

Adult↗
PubMed1980

Postcoital contraception with an injectable estrogen preparation (Org 369 - 2).

In one-hundred women age 15 to 45, postcoital contraception was attempted with a "morning-after" injection consisting of 12.5 mg estradiol-benzoate and 10 mg of estradiol-phenylpropionate. Plasma estradiol-178, progesterone, LH, FSH and Prl were measured by specific radioimmunoassays and BBT was recorded. In 97.8% the injection was given within 48 hours after unprotected coitus. The medication induced minimal cycle and bleeding pattern changes. The rate of side effects was low. The incidence of pregnancies due to medication failure was 3%. The plasma hormone patterns before and under therapy are demonstrated and drug-induced changes discussed.

Adolescent↗
PubMed1982

A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent.

Six hundred ninety-two women were enrolled in a multicenter clinical trial to evaluate a combination of ethinyl estradiol and dl-norgestrel as a postcoital contraceptive. When compared with various formulas predicting the probability of pregnancy in this group, the number of pregnancies observed appears to be reduced by approximately 84%. The combination of 200 micrograms of ethinyl estradiol and 2 mg of dl-norgestrel seems to be effective as a postcoital contraceptive with several advantages over estrogens alone.

Adolescent↗
PubMed2003

Postcoital contraception in Turkey.

OBJECTIVES: The purpose of this article is to determine the knowledge status of women concerning postcoital contraception when they turn to curettage in order to terminate an undesired pregnancy. METHODS: This defining study has been carried out at a maternity hospital in Izmir on pregnant women admitted for curettage. We interviewed 150 pregnant cases using an improbability sampling method. RESULTS: We discovered that 48.7% of women had avoided pregnancy before curettage by withdrawal before ejaculation. When we investigated the method used after uncontrolled coitus, 27.3% of cases reported vaginal douche while 12.7% indicated curettage. After having an unprotected coitus or failure in contraceptive methods 99.3% of the women indicated they would report to health institutes to utilize postcoital methods if they were familiar with them. CONCLUSIONS: Postcoital contraception may be a solution for undesired pregnancies.

Adult↗
PubMed1983

Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.

A combination of 1.0 mg dl-norgestrel and 0.1 mg ethinylestradiol was administered orally at 18 hours after the detection of luteinizing hormone rise and again at 30 hours in five healthy volunteers with normal menstrual cycles. The effects on ovarian function were studied by comparing the daily serum levels of progesterone (P), 17 alpha-hydroxyprogesterone, and estradiol (E2) measured in a control (placebo) cycle with those in two consecutive treatment cycles. Treatment did not alter the steroid levels in one subject. P was suppressed in one or both treatment cycles of four subjects. E2 was suppressed in both treatment cycles of one subject and produced widely fluctuating patterns in another. The hormonal patterns in the two consecutive treatment cycles of the same individual were similar in all but one instance, where only the P level in the second treatment cycle was diminished. These results showed that this treatment can elicit steroidogenic responses of varying degrees and duration. The contraceptive action may lie in the altered P and/or E2 level at certain points in the menstrual cycle.

17-alpha-Hydroxyprogesterone↗
PubMed1988

Postcoital contraception: some characteristics of women who use this method.

This paper describes some of the characteristics of the women who attended a medical clinic requesting postcoital contraception. The information is derived from 871 observations in 653 women who requested this contraception. The mean age of women at the time of first request for this method was older than expected (21.9 years) and the mean time from first coitus to first request for the method was longer than expected (2.7 years). Previous pregnancy with therapeutic abortion was reported by 11.3% of the women. Multiple users of the method were younger at their first visit, and more likely to report a previous pregnancy. The method of contraception used before and after the need for postcoital contraception tended to be the same. Barrier method users have need of this method either for use when they fail to use their barrier method or for use when their barrier method fails. The need for more general availability of this method is discussed.

Abortion, Induced↗
PubMed1979

Mode of action of DL-norgestrel and ethinylestradiol combination in postcoital contraception.

Possible mechanisms of action of a combination of ethinylestradiol (EE) and dl-norgestrel as a postcoital contraceptive agent were studied in 12 healthy female volunteers. An oral dose of 0.1 mg of EE and 1.0 mg of dl-norgestrel was given at the predicted time of ovulation and again 12 hours later. Serum luteinizing hormone, prolactin, progesterone, 17 alpha-hydroxyprogesterone, and estradiol were measured by specific radioimmunoassays in blood samples obtained daily from the 8th day of the menstrual cycle to the 1st day of menses. Hormone profiles suggested that the medication elicited a range of individual variations in pituitary and/or ovarian responses. Histologic examination of the endometrium consistently showed significant alteration in endometrial development with a dissociation in maturation of glandular and stomal components. This postcoital contraceptive acts either by (1) suppressing ovulation or (2) disrupting luteal function by acting directly on the corpus luteum or by interfering with appropriate endometrial responses to ovarian steroids.

Contraceptives, Postcoital↗